Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.

Journal of medical economics - 1 Aug 2020

Pruis Sil-Ling, Jeon Yunjoo Karris, Pearce Fiona, Thong Bernard Yu-Hor, Aziz Mohamed Ismail Abdul

Abstract excerpt

Aims: Allopurinol is the most common urate lowering therapy (ULT) used to treat gout but may cause life-threatening severe cutaneous adverse reactions (SCAR) in a small number of patients. Risk of SCAR is increased for patients with the HLA-B*58:01 genotype. When alternative ULT is required, febuxostat or probenecid are recommended. The aim of this study was to conduct a cost-utility analysis of sequential ULT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allopurinol
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gout Suppressants

Share to Kidney Function Tests

Share to Quality-Adjusted Life Years

Share to Singapore

Share to Uric Acid

Source

Identifiers

PMID: 32301360
DOI: 10.1080/13696998.2020.1757456

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.PMID 32301360Read ↗

Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.Semantic proximity Read ↗

Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.Semantic proximity Read ↗

Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?Semantic proximity Read ↗

Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.Semantic proximity Read ↗

An Updated Economic Evaluation of HLA ‐B*58:01 Genotype Testing in Gouty Patients for Preventing Severe Allopurinol Hypersensitivity in ThailandSemantic proximity Read ↗

Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.Semantic proximity Read ↗

Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore.Semantic proximity Read ↗

HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.Semantic proximity Read ↗

Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescriptionSemantic proximity Read ↗

Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model.Semantic proximity Read ↗

Strimvelis® for Treating Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: An Evidence Review Group Perspective of a NICE Highly Specialised Technology EvaluationSemantic proximity Read ↗

Cost-Utility of Dalbavancin as a Treatment Option for Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in CanadaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.